###### Strengths and limitations of this study

-   Covered all guidelines published on diabetes over the past one decade in China.

-   It has the potential to contribute significantly in the upscaling guideline development

-   Conducted a subgroup analysis based on different classification criteria and compared scores of each domain subgroup analyses.

-   The AGREE II instrument only assesses the reporting of the different items and not the content validity of the recommendations.

Introduction {#s1}
============

Diabetes mellitus has become one of the leading causes of mortality and burden of disease worldwide, especially in China, which is now home to the largest number of diabetics worldwide.[@R1] The prevalence of diabetes mellitus among adults in China has increased substantially in recent decades, rising from 0.7% in 1980 to 10.9% in 2013.[@R1] During the recent years, the government and organisations have started to pay more attention to this chronical disease, and national clinical practice guidelines (CPGs) for diabetes mellitus are also increasingly produced and disseminated. CPGs are defined as 'statements that include recommendations intended to optimise patient care, which are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options'.[@R5] High-quality guidelines provide explicit recommendations for clinical practice, helping to manage health conditions and reduce the use of unnecessary, ineffective or harmful interventions.[@R6] CPGs for diabetes mellitus have been developed to help optimise the management of the condition and improve the quality, appropriateness and cost-effectiveness of patient care.[@R7] However, the potential of CPGs to improve patient care and resource use largely depends on the rigour of their development as well as the dissemination and implementation strategies.[@R8] To the best of our knowledge, there has been no systematic evaluation of guidelines on diabetes mellitus in China. The growing number of guidelines may result in increasing variability and conflicts among guideline recommendations. China currently lacks capacity for evidence-based guideline development and coordination by a central agency. Most Chinese guideline users rely on recommendations developed by professional groups that lack demonstration of transparency (including conflicts of interest (COIs) management and evidence synthesis) and quality. In addition, misperceptions about the role of guidelines in assisting practitioners as opposed to providing rules requiring adherence, and a perception that traditional Chinese medicine (TCM) cannot be appropriately incorporated in guidelines are present.[@R10] Hence, we aimed to systematically review the existing Chinese guidelines for diabetes mellitus, assess their quality and eventually help Chinese guideline developers better follow methodological standards while developing guidelines in the future. However, the assessment of the content validity is not a part of this review as the instrument used in the review only assesses the reporting of the different items and not the clinical content. We will pay attention to the consistency of recommendations in different included guidelines loosely as well.

Identification of guidelines {#s1a}
----------------------------

We conducted a computerised search of four major academic databases: Chinese Biomedical Literature database (<http://www.sinomed.ac.cn/>), WanFang database (Chinese Medicine Premier, <http://www.wanfangdata.com.cn/>), VIP (Chinese Journals Full-text database, <http://data.whlib.ac.cn/>) and China National Knowledge Infrastructure (<http://www.cnki.net/>). We used the same search strategy in all databases and restricted the search to guidelines published in China from January 2007 through April 2017. The search strategy included Chinese translations of terms such as 'guideline' and 'diabetes mellitus' ([table 1](#T1){ref-type="table"}). In addition, we searched guidelines for diabetes mellitus on several websites and search engines, including Google Scholar and Chinese Diabetes Mellitus Association (<http://www.zhtnbxh.org/>). If full text of guidelines could not be found, we contacted the author or the development agency. We also searched all articles published in *Chinese Journal of Evidence-Based Medicine*, *Chinese Journal of Diabetes Mellitus* and *Chinese Journal of Diabetes* before April 2017 manually. To identify guidelines published outside of indexed journals, our search of key databases was supplemented with a search of the grey literature. Grey literature were covered by systematically searching publications of all relevant diabetes societies and associations and other health organisations for CPGs that meet our inclusion criteria. We searched the PubMed specifically restricted to Chinese CPGs to retrieve the Chinese diabetes CPGs. Old or variant versions of guidelines where a new version was available, and guidelines not originally developed in China (such as Chinese versions of foreign CPGs, and adapted versions of CPGs from other countries), were excluded.

###### 

Search strategies

                                    Search terms                                                                     Explanation
  --------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  \#1[\*](#tblfn1){ref-type="fn"}   'zhinan' or 'zhiyin' or 'gongshi' or 'caoan'                                     'zhinan','zhiyin','gongshi' and 'caoan' mean 'guideline' in Chinese
  \#2                               'tangniaobing' or 'xiaokezheng' or DM or NIDDM or IDDM or MODY or T2DM or T1DM   'tangniaobing' means diabetes mellitus in Chinese. 'xiaokezheng' is a term used by doctors of traditional Chinese medicine to refer to diabetes mellitus
  \#3                               \#1 and \#2                                                                      

\*We used Zhinan as a subject heading in the Chinese Biomedical Literature database, and the terms 'zhinan','zhiyin','gongshi' and 'caoan' in the title of the paper in the other three full-text databases Wan Fang, VIP and China National Knowledge Infrastructure.

Screening and data extraction {#s1b}
-----------------------------

All studies were independently reviewed for eligibility by two researchers (LK, LL). Disagreements were resolved by face-to-face discussion, or in case of persistent disagreement, by consultation with a third researcher (YG). We first screened the titles and abstracts, and in the next steps, the full texts of publications considered relevant. All included studies were imported in ENDNOTE. We first conducted one preliminary trial of data extraction. The extraction strategy was then discussed and agreed on by all researchers, and formal data collection was performed. Data extraction was done in Excel. For the validity and accuracy of data, the data collection was completed by two researchers independently. Disagreements were resolved by discussion.

Evaluation of guidelines {#s1c}
------------------------

AGREE II is an international, rigorously developed and validated instrument for evaluating CPGs.[@R11] It consists of 23 key items organised within 6 domains. Each item in a domain is given a score from 1 (strongly disagree) to 7 (strongly agree). The score for each domain is obtained by summing all the scores of the individual reviewers for all items in a domain and then standardising as follows: (obtained score−minimal possible score)/(maximal possible score−minimal possible score).[@R13] All authors who were involved in assessing the guidelines using AGREE II had taken a formal training on the AGREE Enterprise website. We initially conducted two rounds of pilot appraisals with a total of 10 guidelines and discussed discrepancies, ensuring that all reviewers came to an agreement in understanding each item of AGREE II. Each guideline was independently evaluated by four reviewers.

Patient and public involvement {#s1d}
------------------------------

Patients were not involved in our study.

Statistical analysis {#s1e}
--------------------

We present the means and SD for AGREE II domain scores, and the number of cases and corresponding percentages for categorical variables. Data for each domain were analysed by Microsoft Excel 2013 and SPSS V.25.0. Intraclass correlation coefficients (ICCs) were used for testing inter-rater reliability among the four reviewers.[@R14] We started the formal appraisal only after ICC reached at least 0.8 in the pilot appraisals. We confirmed whether data were in accordance with normal distribution at the beginning with SPSS V.25.0. If it was normally distributed, we would use one-way analysis of variance to compute the p value between the differences of multigroups. If it was not normally distributed, we descripted the data in median (IQR). And then we tested the statistical significance of differences among several subgroups (≥2) using Kruskal-Wallis test. The independent sample t-test was used to compare the statistical significance of differences between two groups. All tests were two-sided, and p values \<0.05 were considered to be statistically significant. Besides, we compared the scores of Chinese diabetes CPGs with those of Chinese CPGs[@R15] and CPGs published worldwide[@R16] of all topics.

Results {#s2}
=======

Literature search {#s2a}
-----------------

Our systematic search yielded 8065 records, of which 3641 were excluded as duplicates. A total of 3979 records were excluded due to irrelevant topic after title and abstract screening, and 335 after reviewing full text. Twenty further guidelines were still excluded after evaluation. Eight guidelines were identified in the supplementary website search, one guideline was retrieved by PubMed search and no guidelines in the manual searches of the three journals. Finally, 98 eligible guidelines were included in our analysis ([figure 1](#F1){ref-type="fig"}).

![Flow chart of the literature search of Chinese clinical practice guidelines (CPGs) for diabetes published between 2007 and 2017. CBM, Chinese Biomedical Literature database; CNKI, China National Knowledge Infrastructure.](bmjopen-2018-022392f01){#F1}

Characteristics of the guidelines {#s2b}
---------------------------------

The publication year of the included CPGs ranged between 2009 and 2017. The year with highest number of published diabetes CPGs (23) was 2011. Nine of the CPGs were updates of previous versions. The databases, exact terms and the time period of the search were accurately described in five guidelines. Seventeen guidelines targeted type 2 diabetes mellitus, two guidelines type 1 diabetes mellitus, two guidelines juvenile diabetes mellitus and one guideline latent autoimmune diabetes mellitus of adults. Some guidelines focused on complications only, including cardiovascular disease (five guidelines), diseases of the nervous system (five guidelines), kidney disease (five guidelines), hypertension (four guidelines), diabetic retinopathy (three guidelines) and diabetic foot (three guidelines). Seven guidelines reported that they received funding from governments, and two guidelines reported that they received funding from other academic organisations. Sixty guidelines were published in the Chinese Science Citation Database (CSCD), and one guideline online in Wiley Online Library (wileyonlinelibrary.com). Characteristics of the guidelines are displayed in online [supplementary file 1](#SP1){ref-type="supplementary-material"}.
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AGREE II results {#s2c}
----------------

The ICC for AGREE II assessment in the study was 0.929 (95% CI 0.910 to 0.942). It indicates that appraisers reached an agreement about the items in AGREE II. The scores of the included guidelines are summarised in [table 2](#T2){ref-type="table"}. The data were not a normal distribution by analysing in the test of normality with SPSS, so the data were descripted in median (IQR). However, the difference of mean score and median score was subtle, mean score could be used to analyse to some extent. Subgroup analysis across domains has been done.

###### 

AGREE II score of guidelines included

  Domains   Content                   Median score (IQR, %)   Mean score (X±SD, %)   Score segmentation (number of guidelines (%))                           
  --------- ------------------------- ----------------------- ---------------------- ----------------------------------------------- ----------- ----------- ---------
  1         Scope and purpose         53.7 (50.0--59.7)       54.8±6.8               0 (0.0)                                         27 (27.6)   71 (72.4)   0 (0.0)
  2         Stakeholder involvement   31.5 (27.3--37.0)       32.1±9.3               21 (21.5)                                       75 (76.5)   2 (2.0)     0 (0.0)
  3         Rigour of development     19.1 (15.3--22.2)       20.2±10.8              81 (82.7)                                       15 (15.3)   2 (2.0)     0 (0.0)
  4         Clarity of presentation   59.3 (50.0--64.8)       56.9±10.9              1 (1.0)                                         27 (27.6)   70 (71.4)   0 (0.0)
  5         Applicability             18.1 (13.9--25.7)       19.2±8.7               74 (75.5)                                       24 (24.5)   0 (0.0)     0 (0.0)
  6         Editorial independence    0.0 (0.0--0.0)          1.6±4.6                98 (100.0)                                      0 (0.0)     0 (0.0)     0 (0.0)

Scope and purpose {#s2d}
-----------------

The median score in this domain was 53.7 (50.0--59.7). The median score was the second highest among the domains. Most guidelines performed well in this domain, with no guidelines scoring below 25%.

Stakeholder involvement {#s2e}
-----------------------

The median score for the overall score for this domain was 31.5 (27.3--37.0). Twenty-eight guidelines referred to methodologists or evidence-based experts in the guideline development stage, and none involved patients in the development process. Only two CPGs scored at least 50%.

Rigour of development {#s2f}
---------------------

Two CPGs scored at least 50% in the domain 'rigour of development'. The overall score in this domain was poor, with a median of 19.1 (15.3--22.2). Five CPGs described the systematic methods for searching and selecting evidence, 40 CPGs described the strengths and limitations of the body of evidence clearly, 29 CPGs used a nominal group technique or consensus-development conference, 81 CPGs considered the health benefits, side effects and risks in formulating the recommendations, 91 CPGs indicated a link between the supporting evidence and the recommendations and 4 CPGs were reviewed externally before publication. 9 guidelines were updated versions of older guidelines, but none of these described a procedure for updating the guideline.

Clarity of presentation {#s2g}
-----------------------

Overall, the mean score for this domain was the highest among all domains, and only one guideline scored \<25%. Recommendations were specific and unambiguous in all CPGs, although to various degrees. Four CPGs did not present the different options for management of the condition or health issue, and in one CPG key recommendations were not identifiable.

Applicability {#s2h}
-------------

The median score for the overall quality score for this domain was 18.1 (13.9--25.7). 14 CPGs provided advice or tools on how the recommendations could be put into practice. Similarly, 14 CPGs described facilitators and barriers to its application. 14 CPGs considered the potential resource implications of applying the recommendations, and 87 CPGs presented monitoring or auditing criteria. 74 guidelines scored \<25% for this domain.

Editorial independence {#s2i}
----------------------

The scores for this domain were the lowest among all domains, with all 98 guidelines scoring \<25%. Only one guideline reported that there were no COIs. 9 CPGs reported that they received funding from governments (seven guidelines) or academic organisations (two guidelines). However, these 9 guidelines failed to report whether the views of the funding body influenced the content of the guideline or not.

Scores of AGREE II in each domain based on different classification criteria {#s2j}
----------------------------------------------------------------------------

We conducted a subgroup analysis based on different classification criteria and compared scores of each domain subgroup analyses. [Table 3](#T3){ref-type="table"} shows the domain scores and p values for different subgroups of the guidelines. It is evident from [table 3](#T3){ref-type="table"} that CPGs of integrated TCM and Western medicine performed clearly better than CPGs on Western medicine or TCM in all domains. Guidelines that reported external funding scored better than guidelines that did not report funding in editorial independence. Guidelines that involved methodologists scored higher than guidelines not reporting methodologists and the differences were statistically significant in 'stakeholder involvement' and 'rigour of development'. To some extent, reporting methodologists could increase the scores in 'stakeholder involvement' and 'rigour of development'. The difference between guidelines published in CSCD and non-CSCD journals was not statistically significant, developing organisation and type of guidelines as well. The results of the subgroup analysis showed that the updated version of the guidelines scored higher than the non-updated guidelines in all five fields (except for 'field six: editorial independence').

###### 

Scores of AGREE II based on different classification criteria

  Subanalysis                                                Number of guidelines (%)   Domain scores (mean±SD, %)                                                   
  ---------------------------------------------------------- -------------------------- ---------------------------- ----------- ----------- ----------- ----------- ----------
  Developing organisation                                                                                                                                            
   Chinese Medical Diabetes Association                      60 (61.1%)                 54.9±6.8                     31.7±8.3    20.7±9.2    58.4±8.4    20.3±8.6    1.3±4.1
   Specially formed group\*                                  18 (18.4%)                 55.1±8.0                     32.8±13.9   19.8±15.8   56.2±12.1   17.9±10.9   2.6±6.5
   National Health and Family Planning Commission            2 (2.1%)                   45.4±9.2                     27.8±2.6    13.5±17.2   41.7±32.7   13.9±0.0    0.0±0.0
   Ministry of Public Health                                 1 (1.0%)                   44.4                         16.7        4.2         29.6        0.0         0.0
   Hospitals                                                 1 (1.0%)                   59.3                         31.5        21.5        59.3        16.7        0.0
   Collaboration of two or more organisations                14 (14.3%)                 56.1±5.5                     33.5±5.3    19.7±9.8    56.0±12.0   18.2±7.2    0.8±3.0
   Others                                                    2 (2.1%)                   52.8±3.9                     39.8±11.8   25.0±7.9    53.7±10.5   18.8±6.9    8.3±11.8
   P value                                                                              0.36                         0.54        0.77        0.18        0.48        0.35
  Type of guidelines                                                                                                                                                 
   Diagnosis and treatment                                   27 (27.6)                  55.8±7.9                     30.3±6.3    18.6±6.6    59.2±7.9    22.3±9.5    1.6±4.8
   Treatment                                                 22 (22.4%)                 54.5±7.8                     33.6±10.8   22.4±14.8   55.6±14.1   20.3±9.0    0.6±3.0
   Management                                                14 (14.3%)                 53.4±6.0                     31.0±6.3    18.3±6.9    56.1±10.3   14.9±5.3    1.2±4.5
   Prevention and treatment                                  9 (9.2%)                   54.9±3.6                     29.2±6.5    20.0±3.8    61.3±3.0    19.6±9.1    1.2±3.5
   Technology†                                               6 (6.1%)                   51.2±2.2                     38.9±6.6    18.6±6.9    53.4±10.0   16.7±4.6    2.8±6.8
   Medication‡                                               5 (5.1%)                   56.7±7.9                     34.8±7.6    22.5±7.5    58.1±11.2   19.2±9.1    0.0±0.0
   Prevention                                                1 (1.0%)                   68.5                         37.0        24.3        64.8        29.2        0.0
   Healthcare                                                1 (1.0%)                   59.3                         14.8        7.6         40.7        15.3        0.0
   Comprehensive§                                            13 (13.3%)                 54.4±6.6                     33.0±14.8   22.2±17.9   54.1±14.6   15.8±8.9    4.1±6.5
   P value                                                                              0.49                         0.25        0.84        0.52        0.19        0.64
  Publication year                                                                                                                                                   
   2009                                                      3 (3.0%)                   59.9±7.7                     26.5±8.8    15.7±6.5    53.1±10.9   22.2±2.8    0.0±0.0
   2010                                                      7 (7.1%)                   52.1±8.1                     28.8±6.2    14.7±4.3    50.8±10.8   13.5±11.9   2.4±6.3
   2011                                                      23 (23.5%)                 56.2±6.5                     32.3±7.3    21.2±6.3    60.5±8.1    22.3±8.6    0.5±2.3
   2012                                                      13 (13.3%)                 53.3±6.2                     34.5±12.9   23.5±17.6   54.6±11.6   16.0±7.2    3.2±6.2
   2013                                                      10 (10.2%)                 53.9±8.5                     27.8±6.3    15.4±4.6    54.3±10.8   19.4±11.2   1.7±5.3
   2014                                                      12 (12.2%)                 56.8±7.8                     32.7±8.4    19.6±5.3    60.6±6.8    22.7±9.7    1.4±4.8
   2015                                                      9 (9.2%)                   54.1±5.6                     31.1±5.9    22.8±5.4    61.7±5.4    20.4±7.6    1.2±3.7
   2016                                                      14 (14.3%)                 53.0±6.1                     32.1±7.5    18.6±9.5    53.2±15.1   16.1±2.9    0.8±3.0
   2017                                                      7 (7.1%)                   56.3±8.0                     38.6±17.7   25.4±24.5   56.3±16.1   17.3±9.8    4.4±7.5
   P value                                                                              0.58                         0.38        0.42        0.20        0.13        0.59
  Western medicine or traditional Chinese medicine                                                                                                                   
   Western medicine                                          78 (79.6%)                 53.7±6.7                     31.2±7.3    18.9±7.3    56.5±11.9   18.2±8.3    1.3±4.4
   Traditional Chinese medicine                              14 (14.3%)                 58.6±5.9                     31.1±7.5    19.9±4.8    58.7±5.6    21.8±9.7    1.6±4.0
   Integrated medicine                                       6 (6.1%)                   59.3±7.9                     44.4±22.1   36.9±31.5   60.8±1.4    24.3±8.5    4.6±7.2
   P value                                                                              0.01                         0.002       0.001       0.53        0.11        0.23
  Participation of methodologists in guideline development                                                                                                           
   Methodologists involved                                   27 (27.6%)                 55.6±7.2                     36.9±11.4   25.2±16.8   58.3±10.0   19.8±6.6    1.4±4.2
   Not reported                                              71 (72.4%)                 54.6±6.9                     30.2±7.6    18.3±6.6    56.4±11.3   19.0±9.4    1.6±4.7
   P value                                                                              0.52                         0.01        0.048       0.45        0.67        0.77
  External funding                                                                                                                                                   
   No reported external funding                              85 (86.7%)                 55.2±6.6                     32.3±8.3    19.7±9.6    56.6±11.4   19.7±8.3    0.5±2.6
   External funding reported                                 13 (13.3%)                 52.6±8.7                     30.6±14.4   23.2±17.0   58.8±6.8    15.9±10.7   8.8±7.5
   P value                                                                              0.19                         0.54        0.25        0.31        0.13        0.001
  Indexation in Chinese Sciences Citation Database (CSCD)                                                                                                            
   Indexed in CSCD                                           60 (61.2%)                 54.0±7.0                     32.4±8.6    20.0±10.4   56.9±10.6   17.8±8.2    2.0±5.2
   Not indexed in CSCD                                       37 (37.8%)                 56.1±6.8                     32.0±10.0   20.8±11.5   57.4±11.4   21.5±9.2    1.0±3.4
   P value                                                                              0.14                         0.65        0.82        0.98        0.46        0.27
  Version                                                                                                                                                            
   Original                                                  81 (82.7%)                 54.8±7.3                     31.9±9.3    19.9±11.5   56.2±0.1    18.9±0.1    1.9±5.0
   Updated                                                   17 (17.3%)                 55.0±4.8                     32.9±9.2    21.4±6.6    60.2±9.4    20.7±6.9    0.0±0.0
   P value                                                                              0.14                         0.43        0.38        0.30        0.20        0.00

\*Groups specifically formed for developing the guideline; members were staff from different hospitals.

†Refers to guidelines about the use of medical equipment, eg, insulin injection needle.

‡Refers to guidelines about the use of specific drugs, eg, insulin.

§Refers to guidelines covering more than two types of guidelines.

Comparison of AGREE II scores between Chinese diabetes CPGs and CPGs published worldwide {#s2k}
----------------------------------------------------------------------------------------

Armstrong *et al* [@R16] used the AGREE II tool to evaluate 415 individual CPGs published between 1992 and 2014. The results showed that the average scores of the guidelines in the six AGREE II domains were 75.8%, 52.6%, 51.3%, 80.0%, 37.1% and 41.8%, respectively, as compared with the Chinese guidelines, which had a larger gap in all domains. Chen *et al* [@R15] used the AGREE II tools to evaluate 269 CPGs in China in all fields, with the results of 64%, 52%, 48%, 81%, 43% and 26%, respectively. The scores of Chinese CPGs on diabetes were clearly higher than those of Chinese CPGs of all topics on average. The scores of Chinese diabetes CPGs were substantially lower than the international average of CPGs on all topics.

Discussion {#s3}
==========

Chinese diabetes CPGs have an advantage in quantity this decade {#s3a}
---------------------------------------------------------------

It is astonishing that almost 100 domestic guidelines of diabetes mellitus have been published in China in just mere one decade. We found that annual number of CPGs for diabetes mellitus published in domestic Chinese journals increased dramatically up to 2011, after which the number has remained fairly stable during the last few years.

The increasing number indicates that more and more Chinese diabetes CPGs are being applied to clinical practice. Government agencies and the general and subspecialty medical societies in China promote the use of domestic guidelines in healthcare instead of merely adopting foreign guidelines, to account for the characteristics and needs of Chinese patients and clinicians. Meanwhile, the number of published randomised controlled trials and systematic reviews in China is increasing quickly, which may be associated with rapid increase in burden of diabetics. This has laid the groundwork for development of guidelines.

Analysis of scores in each domain {#s3b}
---------------------------------

An increasing amount of CPGs are being published. However, there is still much progress to be made as for quality of each domain. In the six major fields of the AGREE II tool scoring system, only the score of domain 1, 'scope and purpose' and domain 4 'clarity of presentation' were \>50%; as such, the scores of the other four fields need to be improved upon. The low score of domain 2, 'stakeholder involvement', was because most of the guidelines included in the present study did not take into account the multidisciplinary intersections of the participants, as well as the preferences and values of the target population. The low score of domain 3, 'rigour of development', means that generally those guidelines failed to show that they have conducted a systematic review on the best available evidences.[@R17] The low score was possibly due to the fact that the reporting on the approach to its development lacked transparency. Several of included guidelines did not report the methods of the systematic literature search, forming their recommendations and screening of evidence. Additionally, the low score of domain 5, 'applicability', suggested that most guidelines development agencies ignored the guidelines' application, and that most guidelines did not provide relevant supporting documents or recommendations or emphasise the promotion and hindrance factors in the application process. In fact, failure to address the issue of implementation and to provide clear, practical advice can have important consequences. The low score of domain 6, 'editorial independence', was likely due to the lack of disclosure of funding sources and related COIs. Only two of the included guidelines describes the methods by which potential COIs were sought and how COIs affected the recommendation development process. Failure to address the issue of implementation and to provide clear, practical advice can have important consequences. The Chinese diabetes guidelines' score was lower than that of international DR guidelines in this field, indicating that the Chinese Guidance Group has not paid enough attention to the interests of the members of the disclosure group and to declaring clearly the views of the sponsors. If a COI is not declared, the recommendations may be affected by multiple interests and biased. It may not be that the quality of the guidelines themselves are low but rather the quality of the non-standard report of the guidelines.[@R13] The low scores of these domains may be due to actual problems in guideline development, but because of the nature of the AGREE scoring, they may also simply be due to insufficient clarity and communication of the process used.[@R19]

Quality of Chinese diabetes CPGs were comparatively low {#s3c}
-------------------------------------------------------

The mean score in each domain of the quality of Chinese diabetes CPGs was tremendously lower than that of CPGs published worldwide. The difference can be at least partly explained by the selection criteria: the review by Armstrong *et al* included guidelines that are indexed in Medline and therefore likely to be of high quality, whereas our study tried to find all guidelines on a specific topic in one country. Besides, there was a huge gap between the Chinese diabetes CPGs and CPGs published worldwide in the domain 'editorial independence': this domain was also the one that had lowest score overall. COIs are a significant issue worldwide, as can introduce bias into almost every step of the guideline development process.[@R20] Our results show that there are serious reporting flaws for potential COIs for the members of the guideline development groups in Chinese CPGs. Most foreign and international organisations, such as WHO, have their own COI disclosure policies for members of guideline panels,[@R21] but until now, only few Chinese guideline-developing organisations have implemented such policies. Unlike in most other countries, in China the majority of guidelines are developed by professional committees, and despite reporting no external funding, many of these guidelines may be supported by pharmaceutical companies. It is critically important that guideline developers attend to declarations of potential COIs in a proactive, reasoned, transparent and defensible manner. An efficient way to decrease the influence of pharmaceutical companies could be to establish a government-controlled public foundation to develop guidelines. Armstrong *et al* [@R16] represented the quality of international CPGs, as compared with the Chinese guidelines, which had a larger gap in the 'rigour of development' and 'editorial independence' domains. The wide variability observed in these scores is worrying, since these domains directly reflect the reliability of the guidelines. Some of the included guidelines did not report the specific process of development and a COI as well. Holmer *et al* [@R22] used the AGREE II tools to evaluate 24 CPGs in the field of blood glucose management of type 2 diabetes mellitus, ultimately gaining results of 64%, 52%, 48%, 81%, 43% and 26%, respectively. Included guidelines in our study covers all contexts involved with diabetes mellitus, while Holmer *et al* only focused on blood glucose management of type 2 diabetes mellitus. That might be the reason why scores of guidelines in study of Holmer *et al* behaved much better than the Chinese diabetes CPGs. Anwer *et al* [@R23] selected seven evidence‐based CPGs for management of type 2 diabetes mellitus in adults after a series of group discussion meetings, and then required results of 89.7%, 82.7%, 82.1%, 95.1%, 77.6% and 87.7%, respectively using the AGREE II tools. We can know that the quality of evidenced-based CPGs were much better to some extent. Chen *et al* [@R15] used the AGREE II tools to evaluate 269 CPGs in China in all fields. These results suggested that the Chinese guidelines still had some problems in terms of participation and application, mainly because of lacked considerations about the participants in development of guidelines, and absence of the relevant report. Therefore, guidelines makers subsequently should consider the participation of multidisciplinary personnel and provide some guidance in application. Besides, several studies revealed that there are considerable variations and even conflicting recommendations concerning type 2 diabetes mellitus management from different guidelines.[@R24]

Factors influencing the quality of CPGs {#s3d}
---------------------------------------

Many factors are capable of influencing the quality of CPGs. From the perspective of the funders, the quality of guidelines developed by organisations reporting a funding source was higher than those that did not report any funding. The scores of guidelines with methodologists taking part were higher than those not reporting methodologists. Evidence-based methods could improve the quality of CPGs, especially in stakeholder involvement and rigour of development. The guideline development groups involved methodological experts who could ensure that methodological checks were correctly applied and that the development process was fully documented.[@R26] Developing guidelines based on the methodology of evidence-based medicine could improve the quality of CPGs.[@R27] Yao *et al* [@R28] conducted a study comparing the quality of TCM CPGs with non-TCM CPGs, and the result showed that the quality of TCM CPGs was much better. The quality of TCM CPGs was higher than that of CPGs for Western medicine, which was compliant with the results of the study of Yao *et al*. It means that traditional medicine has drawn a lot of attraction and the relevant studies are becoming more scientific.

Suggestions based on the results of the Chinese diabetes guidelines {#s3e}
-------------------------------------------------------------------

First, evidence-based medicine emphasises focusing on the current optimal clinical medicine and clinicians' skills, as well as taking patients' preferences and values into consideration. Guideline development based on the methodology of evidence-based medicine could improve the quality of CPGs. The development of guidelines should incorporate multidisciplinary experts. Second, the guidelines can be registered during their development and should follow the contents of these to increase their transparency. Third, the promotion and impediment factors should be described in detail during the guidelines application process, while supporting tools for how the recommendations are to be applied in practice should be offered. Fourth, the development team members must also clearly state whether there are any potential COIs, and it is recommended that the editor of the medical journal ask the guidelines developers to provide a COI statement for all participating members as an attachment when delivering the guidelines.[@R29] Fifth, a central agency in China directing the development of evidence-based guideline is definitely required and a call for more rigorous training of guideline developers in China is warranted. As well as the quality of evidence like meta-analyses and randomized controlled trial needs to be improved.[@R30] Sixth, a series of tools could be used to standardize the development of guidelines, such as that the guidelines report should follow the RIGHT report statement in order to ensure the transparency of the guidelines. Grading of Recommendations Assessment, Development and Evaluation curriculum vitae (GRADE CV) can help guideline developers assess a methodologist's expertise with methods and tasks.[@R31]

Strengths and limitations {#s3f}
-------------------------

Our review has several strengths. First, the systematic review of CPGs for diabetes mellitus quality attempted to cover all guidelines published on diabetes over the past one decade in China. Our structured and explicit approach increases the validity of the findings. Second, we used the AGREE II instrument, which is a scientific and valid tool to assess the quality of CPGs. Furthermore, we conducted two rounds (for a total of 10 guidelines) of pilot appraisals and resolved disagreements, which further enhanced the confidence in our results. The extensive search strategy covering both indexed and grey literature, use of multiple appraisers who will complete training and calibration to assess the quality of CPGs and application of the AGREE II instrument, which has established validity and reliability, are all strengths of this review and may help the delivery of better care.

This review has also limitations. Our study was restricted to English and Chinese language guidelines, which excluded a small number of additional guidelines. Furthermore, CPG developers did not report all the details in developing guidelines even if they included some of the items listed in AGREE in process. Therefore, the score of AGREE II may underestimate the methodological quality of guidelines. Lastly, the AGREE II instrument only assesses the reporting of the different items and not the content validity of the recommendations. Currently, there is an ongoing research project, the AGREE‐REX: Recommendation Excellence project that aims at developing and validating a new tool that will complement the AGREE II by assessing the clinical credibility and implementation of CPGs.[@R32] Current review covers the period from 2007 to 2017, however comparison was made, with 2010 and 2012 publication data. Clinical guideline development is a very dynamic process that progresses every year, so the comparison should just be a reference.

Conclusion {#s4}
==========

A large number of CPGs for diabetes mellitus have been produced in China. Generally speaking, the quality of Chinese diabetes CPGs remain unsatisfactorilyin comparison with other guidelines according to the evaluation by the AGREE II instrument. However, there is still room for improvement, especially in the aspect of editorial independence. Reporting the full texts of CPGs and COIss according to AGREE II checklists and abiding to the principles of evidence-based medicine can further improve the quality of guidelines.
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